Why the Botanix share price could crash lower on Wednesday

The Botanix Pharmaceuticals Ltd (ASX:BOT) share price looks set to crash lower on Wednesday following a disappointing study result…

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It looks set to be a disappointing day of trade for the Botanix Pharmaceuticals Ltd (ASX: BOT) share price on Wednesday.

The cannabis-focused medical dermatology company's shares look set to be sold off after a disappointing study result.

What did Botanix announce?

Late on Tuesday night the company released topline data from its Phase 2 BTX 1503 study. This study was evaluating its safety and efficacy in patients with moderate to severe acne and preparations for a Phase 3 clinical program.

Expectations were high that BTX 1503 could become the new standard of care for acne sufferers, replacing existing treatment options that come with horrific side effects.

According to Botanix's release, its 12-week randomised, double blind, vehicle-controlled study enrolled 368 patients with moderate to severe acne across 35 dermatology sites in Australia and the USA.

Unfortunately, the topline data revealed that the primary endpoint (aim) of reducing inflammatory lesions did not achieve statistical significance.

And while the secondary endpoint of reducing non-inflammatory endpoints was statistically significant, the primary endpoint is the one that matters. Especially given that other promising drugs under development are also aiming to leverage the antimicrobial properties of synthetic cannabidiol in a similar way.

However, there is a glimmer of hope for Botanix and its shareholders. While its result was not statistically significance, management blamed this on an abnormally positive result from a placebo group. Discounting this, the result is potentially a positive.

Vince Ippolito, President and Executive Chairman of Botanix said: "We are pleased with the overall efficacy outcomes, clean safety profile and highly significant Australian data. We are very thankful to all of the investigators and patients who helped Botanix rapidly complete this Phase 2 study."

What now?

Management appears intent on trying to commercialise the product despite this disappointing result.

It advised that "Botanix is moving forward with its preparations for Phase 3 clinical program and planning an end-of-Phase 2 meeting with the US Food and Drug Administration."

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Fallers

A male investor wearing a blue shirt looks off to the side with a miffed look on his face as the share price declines.
Share Fallers

Why COG, Karoon Energy, Netwealth, and Pilbara Minerals shares are dropping today

These ASX shares are ending the week deep in the red. But why?

Read more »

A woman with a sad face looks to be receiving bad news on her phone as she holds it in her hands and looks down at it.
Share Fallers

Why Evolution Mining, Karoon Energy, ResMed, and Sayona Mining shares are dropping today

These ASX shares are having a tough session. But why?

Read more »

A young woman wearing a blue and white striped t-shirt blows air from her cheeks and looks up and to the side in a sign of disappointment after the ASX shares she owns went down today
Share Fallers

Why Australian Strategic Materials, Boral, Dubber, and Macquarie Technology are falling today

These shares are having a tough hump day. But why?

Read more »

a sad gambler slumps at a casino table with hands on head and a large pile of casino chips in the foreground.
Share Fallers

'Catastrophic' risk: Why Star shares have lost 25% in 4 days

The outcome of this inquiry could determine whether Star Entertainment hits Blackjack or bust.

Read more »

A male investor erupts into a tantrum and holds his laptop above his head as though he is ready to smash it, as paper flies around him, as he expresses annoyance over so many new 52-week lows in the ASX 200 today
Share Fallers

Why Domino's, Macmahon, Star, and Zip shares are sinking today

These ASX shares are falling more than most today.

Read more »

A young woman holds an open book over her head with a round mouthed expression as if to say oops as she looks at her computer screen in a home office setting with a plant on the desk and shelves of books in the background.
Share Fallers

Why Avita Medical, NextDC, Predictive Discovery, and Star shares are tumbling today

These shares are starting the week in the red.

Read more »

A male investor wearing a blue shirt looks off to the side with a miffed look on his face as the share price declines.
Share Fallers

Why Avita Medical, Cettire, Domino's Pizza, and Star shares are falling today

These ASX shares are having a tough end to the week. But why?

Read more »

Three guys in shirts and ties give the thumbs down.
Share Fallers

Why Avita Medical, Netwealth, Peninsula Energy, and Zip shares are sinking today

These ASX shares are having a tough session. But why?

Read more »